<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27579753</article-id>
      <article-id pub-id-type="pmc">4999116</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20163808</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Porphyria cutanea tarda in a HIV- positive patient<xref ref-type="fn" rid="fn1">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Franzon</surname>
            <given-names>Val&#xE9;ria Aparecida Zanela</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mikilita</surname>
            <given-names>Emanuella Stella</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Camelo</surname>
            <given-names>Fernanda Henriques</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Camargo</surname>
            <given-names>Rosana</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Pontif&#xED;cia Universidade Cat&#xF3;lica do
Paran&#xE1; (PUCPR) - Curitiba (PR), Brazil.</aff>
      <aff id="aff2"><label>2</label>Funda&#xE7;&#xE3;o Pr&#xF3;-Hansen - Curitiba (PR),
Brazil.</aff>
      <aff id="aff3"><label>3</label>Hospital Oswaldo Cruz - Curitiba (PR), Brazil.</aff>
      <author-notes>
        <corresp id="c1">Mailing address: Emanuella Stella Mikilita, Rua Brigadeiro Franco,
1.491, ap. 702, Centro, 80420-200 - Curitiba - PR, Brazil. E-mail:
<email>manu.miki@hotmail.com</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Jul-Aug</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Jul-Aug</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>4</issue>
      <fpage>520</fpage>
      <lpage>523</lpage>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>6</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>1</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>This is a case report about Porphyria cutanea tarda (PCT) and its relationship
with the infection caused by the human immunodeficiency virus (HIV). Cutaneous
porphyria is an illness caused by enzymatic modification that results in partial
deficiency of uroporphyrinogen decarboxylase (Urod), which may be hereditary or
acquired. Several studies suggest that HIV infection associated with cofactors
might trigger the development of porphyria cutanea tarda. In this case report,
we present a patient infected with HIV, who after the introduction of
antiretroviral therapy (ART) enjoyed clinical improvement of porphyria cutanea
tarda symptoms.</p>
      </abstract>
      <kwd-group>
        <kwd>Porphyria cutanea tarda</kwd>
        <kwd>HIV</kwd>
        <kwd>Risk factors</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Porphyrias are rare metabolic disorders which are characterized by an abnormality in
the biosynthesis of heme complex by erythrocytes, due to an enzymatic deficiency in
the production of porphyrin precursors.<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r3" ref-type="bibr">3</xref></sup></p>
      <p>They can divided into four types, according to their characteristics. The sporadic
form (Type I), also named "acquired", is characterized by a decreased hepatic
activity of uroporphyrinogen decarboxylase (Urod) while the disease is active. The
hereditary form of porphyria cutanea tarda (PCT) (Type II) is a dominant autosomal
disease with genetic mutations of the <italic>Urod</italic> gene and is associated
with family history. The toxic form of PCT (Type III) is characterized by its
sporadic nature. The hepatoerythropoietic form of porphyria (Type IV) is caused by a
homozygotic defect of <italic>Urod</italic>. The clinical courses are very
similar.<sup><xref rid="r4" ref-type="bibr">4</xref></sup></p>
      <p>PCT usually affects middle-aged individuals, over 40 years old.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> The disease has as main triggering
factors: alcohol, iron, estrogen, hepatitis C virus (HCV), human immunodeficiency
virus (HIV), polychlorinated hydrocarbons and hemodialysis/chronic renal failure
(CRF).<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup></p>
      <p>The interest in reporting this PCT case is based on the rarity of the disease and
questioning HIV as the only triggering factor.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Male patient, 54 years old, white and merchant, had been infected with HIV for
approximately 20 years. He underwent several antiretroviral therapies (ART),
nevertheless in 2012 he abandoned treatment. In the beginning of 2013, he presented
vesicular and bullous lesions, with citrine yellow content, on the back of hands,
upper limbs and face (<xref ref-type="fig" rid="f1">Figure 1</xref>). In
photoexposed areas, he presented hyperpigmentation, erosions, miliary and atrophic
scars. In February 8<sup>th</sup>, 2013 tests revealed CD4 count = 24 cells/mm, CD8
= 853 cells/mm and viral load = 4,439 copies/ml (b-DNA technique).</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Ulcerated lesions and miliary atrophic scars on the nose, lips and
forehead region. Ulcerated ruptured bullae on the pinna and bullae with
citrine yellow content on the fingers</p>
          </caption>
          <graphic xlink:href="abd-91-04-0520-g01"/>
        </fig>
      </p>
      <p>He reported tuberculosis, cryptococcal meningitis, pneumocystic pneumonia, esophageal
candidiasis and renal failure (by tenofovir).</p>
      <p>In lab tests, liver biochemistry showed TGP = 101 U/L, TGO = 44 U/L and GGT = 127
U/L. Serological tests for hepatitis B and C were not reagent.</p>
      <p>Uroporphyrinogen dosage in the urine was negative, which may have occurred due to
delay in the analysis of the urine or inadequate collection. However, urine
fluorescence test with Wood's lamp was positive. The patient was taken to a
dermatology clinic where he was guided to collect his urine. His urine was
immediately analyzed in a dark room with a Wood's lamp along with the urine from the
lab staff. It presented a faint reddish-pink fluorescence, confirming the presence
of uroporphyrins (<xref ref-type="fig" rid="f2">Figure 2</xref>).
Anatomopathological examination showed, in a lesser magnification, skin with
subepidermal blister, dermal papillae preserved on the site of epidermal detachment
and, in the dermis, a minimal inflammatory perivascular lymphocytic infiltrate
(<xref ref-type="fig" rid="f3">Figure 3</xref>). With greater augmentation
hyaline material deposited around blood vessels was revealed, which is consistent
with a diagnosis of PCT. The situation evolved to clinical improvement after
reinstating ART with lamivudine (150 mg every 12 hours), didanosine (400 mg / day)
and atazanavir (200 mg / day) (<xref ref-type="fig" rid="f4">Figure 4</xref>).</p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Urine fluorescence test with Wood lamp. The test on the right is the
patient&#x2019;s, which presented a faint reddish-pink fluorescence, confirming
the presence of uroporphyrin. The one on the left shows the examiner&#x2019;s
urine (control)</p>
          </caption>
          <graphic xlink:href="abd-91-04-0520-g02"/>
        </fig>
      </p>
      <p>
        <fig id="f3" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Anatomopathological examination of cutaneous lesions. In a lesser
augmentation, skin with subepidermal blister (arrow&#x2019;s head), preserved
dermal papillae at the site of epidermal detachment (black arrows) and,
in the dermis, a minimal inflammatory perivascular lymphocytic
infiltrate. In the detail, in a great augmentation, hyaline material
deposited around blood vessels (red arrows)</p>
          </caption>
          <graphic xlink:href="abd-91-04-0520-g03"/>
        </fig>
      </p>
      <p>
        <fig id="f4" orientation="portrait" position="float">
          <label>Figure 4</label>
          <caption>
            <p>Clinical aspect after reintroduction of ART. Remission of bullous lesions
and reepithelialization of nose, pinna and hand, with areas of
hypochromia</p>
          </caption>
          <graphic xlink:href="abd-91-04-0520-g04"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Porphyrias are metabolic disorders characterized by an abnormality in the
biosynthesis of heme complex by erythrocytes, caused by deficiency of the Urod
enzyme. With that, porphyrins - uroporphyrin and 7-carboxyl-porphyrinogen - are
cumulative, and may be excreted in the urine and feces or deposited in various
tissues throughout the body.<sup><xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r4" ref-type="bibr">4</xref></sup></p>
      <p>The deposition of porphyrins in the skin causes cutaneous photo-sensitization,
because they are unable to store energy from light, which is released to the skin as
a photochemical reaction, causing cutaneous damage.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup></p>
      <p>Clinical manifestations are: skin fragility, vesicles and bullae (tense, with hyaline
content), followed by erosion and crusts, which occur mainly in areas exposed to the
sun and trauma areas, such as face and back of hands and feet. Hyperpigmentation of
areas exposed to the sun may occur. There can still be hypertrichosis, sclerodermoid
plaques, scarring alopecia, premature aging, solar sclerodermoid plaques, scarring
alopecia, premature aging, solar elastosis and onycholysis. Systemic manifestations
are: peripheral neuropathy, palmar fibromatosis, hearing loss, insomnia, personality
disorders, conjunctivitis, nausea, anorexia, diarrhea and constipation. <sup><xref rid="r3" ref-type="bibr">3</xref></sup></p>
      <p>The association of HIV with PCT was initially acknowledged in 1987. There are cases
reported in which PCT starts in the primary phases of the infection and others in
which the development of PCT is late. In most of the reports, there is association
of risk factors, suggesting that the combination of these factors causes hepatic
lesions and that HIV infection makes them worse.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r3" ref-type="bibr">3</xref></sup> However, there are
reports describing the development of PCT in patients who presented infection by HIV
as the single risk factor.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r8" ref-type="bibr">8</xref></sup></p>
      <p>The risk factors are: alcohol, hereditary hemochromatosis, estrogen, HCV, HIV,
polychlorinated hydrocarbons, chronic renal failure and smoking.<sup><xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r5" ref-type="bibr">5</xref></sup></p>
      <p>The physiopathology of PCT and HIV association is not totally understood, however the
authors suggest that HIV carriers have altered steroid metabolism, which increases
the production of endogenous estrogen and, consequently, interferes in the synthesis
of heme, causing PCT. HIV infection is the cause of abnormal excretion of
porphyrins, even with no clinical evidence of PCT.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup></p>
      <p>Some studies suggest that PCT may be caused by ART.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup> On the other
hand, other studies report improvement of patients after the start of ART.<sup><xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Treatment consists of identification and elimination of the causing factor.
Phlebotomy could be performed weekly, collecting 500 ml per session, until
hemoglobin reaches a level lower than 10 g/dl, or serum iron reaches 50 g/dl to 60
g/dl or less, or even porphyrins in the urine reach a level lower than 400
&#xB5;g. Oral chloroquine therapy is also used, twice a week, at low doses (125 mg
to 250 mg). Cimetidine is also described as a therapeutic option for PCT, at 800
mg/day.<sup><xref rid="r3" ref-type="bibr">3</xref></sup></p>
      <p>HIV may play an independent role in causing PCT. Of all known risk factors, HIV was
the only one present in the reported case. After the reintroduction and correct use
of ART (its use was irregular), there was clinical remission of the disease, which
also suggests that HIV and high levels of viral replication may be direct inducers
of PCT.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work performed at Pontif&#xED;cia Universidade Cat&#xF3;lica do Paran&#xE1;
and at Hospital Oswaldo Cruz -Curitiba (PR), Brazil.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="COI-statement">
        <p>Conflict of interest: None.</p>
      </fn>
    </fn-group>
    <ack>
      <title>ACKNOWLEDGMENTS</title>
      <p>We would like to specially thank the pathology service of Hospital das
Cl&#xED;nicas de Curitiba and physician Ricardo Hohmann Cami&#xF1;a, who
performed the anatomopathological tests and supplied photographs of the slides used
in this study.</p>
    </ack>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conde Almeida</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Villa</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Bedin</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Porfiria cut&#xE2;nea tarda no paciente infectado pelo
v&#xED;rus da imunodefici&#xEA;ncia adquirida</article-title>
          <source>Med Cutan Iber Lat Am</source>
          <year>2010</year>
          <volume>38</volume>
          <fpage>91</fpage>
          <lpage>93</lpage>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elder</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Uroporphyrinogen decarboxylase</article-title>
          <source>J Bioenerg Biomembr</source>
          <year>1995</year>
          <volume>27</volume>
          <fpage>207</fpage>
          <lpage>214</lpage>
          <pub-id pub-id-type="pmid">7592567</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vieira</surname>
              <given-names>FMJ</given-names>
            </name>
            <name>
              <surname>Martins</surname>
              <given-names>JEC</given-names>
            </name>
          </person-group>
          <article-title>Porfiria Cut&#xE2;nea Tardia</article-title>
          <source>An Bras Dermatol</source>
          <year>2006</year>
          <volume>81</volume>
          <fpage>573</fpage>
          <lpage>584</lpage>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardes Filho</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>FN</given-names>
            </name>
            <name>
              <surname>Castro</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Dobao</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lyra</surname>
              <given-names>MR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>HAART: a risk factor for development of porphyria cutanea
tarda?</article-title>
          <source>Rev Soc Bras Med Trop</source>
          <year>2012</year>
          <volume>45</volume>
          <fpage>764</fpage>
          <lpage>767</lpage>
          <pub-id pub-id-type="pmid">23295885</pub-id>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Egger</surname>
              <given-names>NG</given-names>
            </name>
            <name>
              <surname>Goeger</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Payne</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Miskovsky</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Weinman</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>KE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Porphyria cutanea tarda: multiplicity of risk factors including
HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase
deficiency</article-title>
          <source>Dig Dis Sci</source>
          <year>2002</year>
          <volume>47</volume>
          <fpage>419</fpage>
          <lpage>426</lpage>
          <pub-id pub-id-type="pmid">11855561</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Celesia</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Onorante</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Nunnari</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mughini</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Mavilla</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Massimino</surname>
              <given-names>SD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Porphyria cut&#xE2;nea tarda in an HIV-1-infected patient after
the initiation of tipranavir/ritonavir: case report</article-title>
          <source>AIDS</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1495</fpage>
          <lpage>1496</lpage>
          <pub-id pub-id-type="pmid">17589203</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gaf&#xE0;</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zannini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gabrielli</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Porphyria cutanea tarda and HIV Infection: Effect of Zidovudine
Treatment on a Patient</article-title>
          <source>Infection</source>
          <year>1992</year>
          <volume>20</volume>
          <fpage>373</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="pmid">1363417</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hassoun</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Corman</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ibrahim</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>An HIV-Infected Woman With Porphyria Cutanea
Tarda</article-title>
          <source>AIDS Read</source>
          <year>2008</year>
          <volume>18</volume>
          <fpage>271</fpage>
          <lpage>272</lpage>
          <pub-id pub-id-type="pmid">18589483</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vasconcelos</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Luz-Rodrigues</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Santos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Filipe</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Desferrioxamine treatment of porphyria cutanea tarda in a patient
with HIV and chronic renal failure</article-title>
          <source>Dermatol Ther</source>
          <year>2014</year>
          <volume>27</volume>
          <fpage>16</fpage>
          <lpage>18</lpage>
          <pub-id pub-id-type="pmid">24502304</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rich</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Mylonakis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Nossa</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chapnick</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <article-title>Highly Active Antiretroviral Therapy Leading to Resolution of
Porphyria Cutanea Tarda in a Patient with AIDS and Hepatitis
C</article-title>
          <source>Digestive Dig Dis Sci</source>
          <year>1999</year>
          <volume>44</volume>
          <fpage>1034</fpage>
          <lpage>1037</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
